Oral
enzyme therapy in hepatitis C patients
Stauder G.,1
Kabil S.2. Oral enzyme therapy in hepatitis C patients. Inter.
Journal of Immunotherapy 1997, Vol. XIII, No. 3/4, pp 153-158, ISSN
0255-9625. SO 112 (19-04-2) - (4-12-1)
1 Mucos Pharma Clinical Research, Malvenweg 2, D-82538 Geretsried,
Germany. 2 Department of
Hepatology, Gastroenterology & Infectious Diseases, Benha University
Hospital, Cairo, Egypt.
7th Interscience World Conference on Inflammation, Antirheumatics,
Analgesics, Immunomodulators, 1997, May 19-21, Geneva, Switzerland -
In an open, randomized, clinical pilot trial, four
groups with 20 hepatitis C patients each were treated with either
'liver support' therapy, with established medications (one group
with ribavirin, one group with a-interferon), or with a novel oral
test drug, Phlogenzym®, a combination of hydrolytic
enzymes with the flavonoid rutosid. The liver transaminases, AST,
ALT, and S-g-GT markedly improved over the period of three months in
the three drug groups, but only marginally in the liver support
group. The best results were found with Phlogenzym®,
which was even superior to ribavirin and a-interferon. The tolerance
of the oral enzymes was excellent. Further clinical trials with
longer observation times, greater numbers of patients, double-blind
and partly placebo-controlled, are under way.